Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Rankweil – page 3

103 clinical trials in Rankweil, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rankweil at a glance
103
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

103 trials in Rankweil

Open in trial search

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:University Of Cologne

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Insel Gruppe AG

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Astrazeneca AB

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Rankweil

What the registry says about research in the country

01 Lung Cancer Research

Groundbreaking studies focusing on both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), evaluating innovative combination therapies and treatment approaches.

  • Extensive-Stage SCLC Treatment
  • Early-Stage NSCLC Management
  • Advanced NSCLC Therapies

Multiple trials exploring immunotherapy combinations with chemotherapy for improved patient outcomes.

02 Surgical Oncology

Research investigating perioperative treatment strategies for resectable lung cancer, combining innovative immunotherapy approaches with standard surgical interventions.

  • Pre-surgical Immunotherapy
  • Post-operative Treatment
  • Combined Modality Approaches

Studies aim to enhance surgical outcomes and prevent disease recurrence in operable cases.

03 Hematologic Oncology

Innovative research in multiple myeloma treatment, evaluating novel therapeutic combinations for transplant-ineligible patients with newly diagnosed disease.

  • Novel Drug Combinations
  • First-line Therapies
  • Treatment Optimization

Focus on improving treatment responses and patient outcomes in blood cancer management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.